ANDA 63253, held by Teva Parenteral. Erythromycin Lactobionate.
As of Nov 16, 2026, ANDA 63253 (Erythromycin Lactobionate), held by Teva Parenteral, was first approved by FDA on Jul 30, 1993, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 30, 1993 | Original application | Approved | None posted |
| Erythromycin LactobionateEQ 500MG BASE/VIAL · injectable;injection | Erythromycin Lactobionate | Discontinued |
| Erythromycin LactobionateEQ 1GM BASE/VIAL · injectable;injection | Erythromycin Lactobionate | Discontinued |
| May 10, 1996 | Supplement 1Labeling | Approved | None posted |
| Jul 30, 1993 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters